SCHEMBL2909528

SCHEMBL2909528

CCOC(=O)c1oc2cc(OC)c(OC)c(OC)c2c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
MAPT P10636 3/20 0.56
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
ALDH1A1 P00352 2/20 0.52
TSHR P16473 1/20 0.52
PPARG P37231 1/20 0.52
NCOA2 Q15596 1/20 0.52
NCOA1 Q15788 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
KDM4E B2RXH2 1/20 0.51
HSD17B10 Q99714 1/20 0.51
NMT2 O60551 5/20 0.46
NMT1 P30419 5/20 0.46
ADRB2 P07550 2/20 0.46
ADRB1 P08588 2/20 0.46
ADRB3 P13945 2/20 0.46
DPP4 P27487 2/20 0.45
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903081 0.83 EDNRA (0.60) MAPTSMN1; SMN2ALDH1A1TSHRPPARG
SCHEMBL3617991 0.81 RAB9A (0.56) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL10460783 0.80 L3MBTL1 (0.61) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3622124 0.80 RAB9A (0.57) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3608849 0.78 RAB9A (0.56) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3607399 0.78 KDM4E (0.76) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2906193 0.77 LMNA (0.55) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL10531197 0.76 RAB9A (0.63) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3646419 0.75 HIF1A (0.51) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2903150 0.74 LMNA (0.53) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400510-B1 CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS KOWA CO (JP) 2010-08-18 EP disclosed
US-7135473-B2 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2006-11-14 US disclosed
US-20040058913-A1 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2004-03-25 US disclosed
EP-1400510-A1 CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6632810-B2 Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation KOWA CO., LTD. (JP) 2003-10-14 US disclosed
US-20030060461-A1 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058913-A1 Cyclic diamine compound with condensed-ring groups HRH4, HRH3, HRH1 L3MBTL1 3363/4885MAPT 4342/4885RAB9A 3447/4885
US-20030060461-A1 Cyclic diamine compound with condensed-ring groups HRH4, HRH3, HRH1 L3MBTL1 3363/4885MAPT 4342/4885RAB9A 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.